PMID: 9165379Apr 1, 1997Paper

Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group

Journal of Affective Disorders
Y LecrubierW Rein

Abstract

Amisulpride, a selective antagonist of D2 and D3 dopamine receptors, acts preferentially on presynaptic receptors increasing dopaminergic transmission at low doses. In a multicentre, 6 months, placebo-controlled trial, amisulpride (50 mg/daily) was compared to imipramine (100 mg/daily) in the treatment of patients with DSM-III-R criteria for primary dysthymia, dysthymia with major depression or major depression in partial remission. A total of 219 patients were included. Both analyses (intention-to-treat and "per protocol' analysis) detected significant differences between groups (active treatment vs. placebo) on all main rating scales (CGI, MADRS, ERD, and SANS). The number of patients reporting at least one adverse event was higher in the imipramine group than in the two other, mainly due to anticholinergic effects. Endocrine symptoms were more frequent in female patients treated with amisulpride. These results confirm the interest of a drug acting on dopaminergic transmission such as amisulpride in the treatment of depressed patients.

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Jan 1, 1992·Progress in Neuro-psychopharmacology & Biological Psychiatry·J RosenthalA Winston
Jan 1, 1990·Modern Problems of Pharmacopsychiatry·N C Andreasen
Mar 1, 1988·Archives of General Psychiatry·J H KocsisJ Sweeney
Mar 1, 1986·Pharmacopsychiatry·D Bobon, M Ansseau
Jan 1, 1974·Modern Problems of Pharmacopsychiatry·L R DerogatisL Covi
Jan 1, 1974·Behavioral Science·L R DerogatisL Covi
Sep 1, 1982·Archives of General Psychiatry·E S PaykelA V Bhat
Jan 1, 1995·The American Journal of Psychiatry·M L Paillère-MartinotF Aubin
Jan 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·P BoyerF Aubin
Aug 1, 1993·The American Journal of Psychiatry·D J HellersteinA Winston
Jan 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·H LooO Fleurot
Jan 29, 2011·Primary Care Companion to the Journal of Clinical Psychiatry·Donna S WightmanJack G Modell
Mar 9, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Albert F G LeentjensPablo Martinez-Martin

❮ Previous
Next ❯

Citations

Nov 19, 2004·Social Psychiatry and Psychiatric Epidemiology·Robert D Goldney, Laura J Fisher
Sep 9, 2008·Psychopharmacology·Hideki TaokaShigetoshi Kuroda
Apr 2, 2009·Psychopharmacology·Atheir I AbbasBryan L Roth
Aug 4, 2009·Psychopharmacology·Peter B Hedlund
Apr 7, 2005·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Apr 5, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Riccardo TortaRoberto Borio
Jul 11, 2002·European Journal of Pharmacology·Giorgio MarcheseLuca Pani
Jul 30, 2002·European Journal of Pharmacology·Giorgio MarcheseLuca Pani
Sep 1, 1999·Journal of Affective Disorders·M SteinerD Wallik
Jun 22, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·W J VerbeeckB Jersky
Jul 20, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J PeuskensA Puech
Jan 22, 2002·International Clinical Psychopharmacology·G B CassanoUNKNOWN AMIMAJOR Group
Jul 18, 2002·Behavioural Pharmacology·P Willner, P J Mitchell
Jul 2, 2005·Journal of Psychiatric Practice·D J Hellerstein
Jul 14, 2005·Journal of Clinical Psychopharmacology·John LiappasAndreas Rabavilas
Mar 11, 2006·International Clinical Psychopharmacology·Jean-Pierre OliéRuoyong Yang
Nov 20, 2010·Current Opinion in Psychiatry·Jun ChenDavid E Kemp
Oct 1, 2006·Acta Neuropsychiatrica·Robert D Goldney, Marcus A Bain
Aug 26, 2006·Clinical Practice and Epidemiology in Mental Health : CP & EMH·Mauro Giovanni CartaEduard Vieta
Jun 27, 2009·Neuropsychiatric Disease and Treatment·Ann M Mortimer
Apr 8, 2000·Drugs & Aging·S BellinoL Ravizza
Apr 21, 2001·Journal of Affective Disorders·N L MillerJ C Markowitz
Feb 15, 2001·Journal of Affective Disorders·H S Akiskal
Jul 20, 2002·Journal of Affective Disorders·Paola RoccaFilippo Bogetto
Jul 15, 2003·Journal of Clinical Psychology·James H Kocsis
Aug 1, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Esteve Brugue, Eduard Vieta
Dec 1, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·R Zanardi, E Smeraldi
Feb 9, 2007·Journal of Clinical Pharmacy and Therapeutics·A F CarvalhoM C Oliveira Lima
Oct 19, 2007·Acta Psychiatrica Scandinavica. Supplementum·M BerkT Norman
Jul 4, 2002·Current Medical Research and Opinion·Ben Green
Aug 30, 2001·Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie·C Göpel, A Marcus
Feb 19, 2013·Neuropharmacology·Lindsay N CatesPeter B Hedlund
Nov 23, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·J-M Vanelle, S Douki
Jan 26, 2010·Behavioural Brain Research·Gor SarkisyanPeter B Hedlund
Nov 25, 2003·The Annals of Pharmacotherapy·Pieter StolkThomas R Einarson
Apr 11, 2000·Journal of Psychopharmacology·M Papp, J Wieronska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.